文献速递慢性肾脏病肾血管病与高血压肾移植

红细胞增多症与慢性肾脏病:综述

Erythrocytosis and CKD: A Review.
PubMed 文献 · Am J Kidney Dis · 2024-04-15

本综述阐述慢性肾脏病(CKD)患者红细胞增多症的病因、发病机制与管理,包括囊性肾病、肾肿瘤、肾移植后、SGLT2抑制剂使用等;强调排除常见获得性原因后应筛查JAK2V617F突变以识别真性红细胞增多症(PV)。

要点

  • CKD患者红细胞增多症虽少见,但未诊治可致血栓事件和死亡。
  • 经典病因包括囊性肾病、肾肿瘤、肾移植后、肾动脉狭窄等。
  • SGLT2抑制剂可诱发红细胞增多,部分揭示PV,需筛查JAK2突变。

核心结论

  • CKD相关红细胞增多症需全面鉴别获得性病因,并及时筛查JAK2V617F以识别PV。
  • SGLT2抑制剂诱导的红细胞增多可能与HIF-2α激活有关,部分病例揭示PV。

研究设计与样本

  • 综述,未报告系统检索范围与样本量。

主要发现

  • 红细胞增多症定义为红细胞浓度超过年龄和性别特异性正常水平。
  • CKD相关红细胞增多症经典病因包括囊性肾病、肾或其它分泌促红细胞生成素肿瘤、高原肾综合征、促红细胞生成素刺激剂过量、雄激素治疗、重度吸烟、慢性肺病、阻塞性睡眠呼吸暂停、IgA肾病、肾移植后红细胞增多症、肾动脉狭窄及先天性病因。
  • SGLT2抑制剂是最新发现的诱导红细胞增多的因素,假说通过激活HIF-2α,部分病例揭示PV。

关键数值与推荐

  • 排除常见获得性病因和/或存在提示性参数时,应考虑原发性红细胞增多症或PV,并筛查JAK2V617F体细胞突变。

临床怎么用

  • 对CKD合并红细胞增多症患者,应系统排查继发性病因,包括药物(SGLT2抑制剂、雄激素、促红细胞生成素刺激剂)及肾脏疾病。
  • 对疑似PV者及时进行JAK2V617F突变筛查,以指导抗血栓等管理。

局限性

  • 本文为综述,未报告系统检索策略、纳入研究数量及偏倚评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Erythrocytosis or polycythemia is defined as an increase in red blood cell concentration above the age- and sex-specific normal levels. Unlike anemia, which is very common in patients with chronic kidney disease (CKD), erythrocytosis is less frequent but requires specific understanding by health care professionals in order to provide the best care. Erythrocytosis, especially when undiagnosed and untreated, can lead to serious thrombotic events and higher mortality. Classic causes of erythrocytosis associated with CKD include cystic kidney diseases, kidney or other erythropoietin-secreting neoplasms, high-altitude renal syndrome, overdosage of erythropoietin-stimulating agents, androgen therapy, heavy smoking, chronic lung disease, obstructive sleep apnea, IgA nephropathy, post-kidney transplant erythrocytosis, renal artery stenosis, and congenital etiologies. After ruling out the common acquired causes of erythrocytosis and/or in the presence of suggestive parameters, primary erythrocytosis or polycythemia vera (PV) should be considered, and patients should be screened for JAK2V617F somatic mutation. The newest entity inducing erythrocytosis is linked to the use of sodium/glucose cotransporter 2 (SGLT2) inhibitors that hypothetically activate hypoxia-inducible factor 2α (HIF-2α) and in some cases unmask PV. This Review focuses on the pathogenesis, renal manifestations and management of PV, the pathophysiology of erythrocytosis induced by SGLT2 inhibitors and the relevance of timely JAK2 mutation screening in these patients.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Aoun M, Jadoul M, Anders HJ, et al. Erythrocytosis and CKD: A Review. Am J Kidney Dis. 2024. PMID: 38621632. doi:10.1053/j.ajkd.2024.02.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。